Drug Positioning Statements

Drug Positioning Statements (DPSs) provide prescribers with recommendations for specific primary / secondary care interface drugs. Prescribers should look for the verdict section, at the bottom of the document in older versions, which describes the APC's recommendation should a rapid appraisal of a drug's positioning locally be required.The DPS document also appraises the evidence and has a drug summary.

These are key documents and prescribers should familiarise themselves with this section of the website and look for new additions regularly

 

TO SEARCH FOR A DOCUMENT, PLEASE USE THE SHOW SEARCH  BUTTON FIELD BELOW.

 NameDescriptionLast Modified  
DPS001 - Exenatide [Type 2 Diabetes treatment].pdf Version: 2.3.3 14 Jul 2017 10:09:41
DPS003 - Aliskiren.pdf Version: 2.1.1 14 Jul 2017 10:09:41
DPS004 - Sitagliptin.pdf Version: 2.1.1 14 Jul 2017 10:09:41
DPS005 - Vildagliptin [Type 2 Diabetes Treatment].pdf Version: 2.1.1 14 Jul 2017 10:09:41
DPS006 - Liraglutide [Type 2 Diabetes treatment].pdf Version: 2.4 21 Mar 2019 18:26:50
DPS007 - Sativex (Cannabis Extract) [moderate to severe spasticity in MS].pdf Version: 3.1.1 14 Jul 2017 10:09:41
DPS008 - Roflumilast.pdf Version: 3.0 01 May 2019 11:41:53
DPS009 - Dronedarone [Cardiac Arrhythmia].pdf Version: 2.1.1 14 Jul 2017 10:09:41
DPS010 - Capsaicin patch (Qutenza) [Peripheral neuropathic pain].pdf Version: 3.1.1 14 Jul 2017 10:09:41
DPS011 - Denosumab [Postmenopausal osteoporosis].pdf Version: 2.1.1 14 Jul 2017 10:09:41
123456789

Share